Activatable Mitochondria-Targeting Organoarsenic Prodrugs for Bioenergetic Cancer Therapy.

Angew Chem Int Ed Engl

Department of Chemical Biology, The MOE Laboratory of Spectrochemical Analysis & Instrumentation, and the Key Laboratory for Chemical Biology of Fujian Province, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen, 361005, China.

Published: January 2021

Despite widespread applications for cancer treatment, chemotherapy is restricted by several limitations, including low targeting specificity, acquired drug resistance, and concomitant adverse side effects. It remains challenging to overcome these drawbacks. Herein, we report a new bioenergetic approach for treating cancer efficiently. As a proof-of-concept, we construct activatable mitochondria-targeting organoarsenic prodrugs from organoarsenic compounds and traditional chemotherapeutics. These prodrugs could accomplish selective delivery and controlled release of both therapeutic agents to mitochondria, which synergistically promote mitochondrial ROS production and induce mitochondrial DNA damage, finally leading to mitochondria-mediated apoptosis of cancer cells. Our in vitro and in vivo experiments reveal the excellent anticancer efficacy of these prodrugs, underscoring the encouraging outlook of this strategy for effective cancer therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1002/anie.202012237DOI Listing

Publication Analysis

Top Keywords

activatable mitochondria-targeting
8
mitochondria-targeting organoarsenic
8
organoarsenic prodrugs
8
cancer therapy
8
cancer
5
prodrugs
4
prodrugs bioenergetic
4
bioenergetic cancer
4
therapy despite
4
despite widespread
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!